康华生物：在建工程转固会严格按照相关规定执行

Core Viewpoint - The company is adhering to accounting standards for the transfer of construction projects to fixed assets, ensuring timely processing based on project progress and readiness for use [1] Group 1 - The vaccine production expansion project is currently under review for supplementary drug production licensing [1] - Upon completion, the project will enhance the production capacity of the company's core product, the freeze-dried human rabies vaccine (human diploid cells) [1]